The RPM Report focuses on a new effort to revise and improve the way the FDA approves proposed proprietary drug names. The agency kicks back about 40 percent of the brand names suggested by sponsors, creating a great deal of frustration with the process. The industry wants more predictability and more insight into what it needs to do to get an approval. But a new pilot program aimed at improving the process is instead raising fears that the name-game will only grow more complex.
- read the story from RPM Report